摘要
目的探究齐拉西酮联合氯氮平治疗难治性精神分裂症的临床疗效。方法本次将2018年1月至2019年6月在我院治疗的难治性精神分裂症患者80例,以随机数表法分成2个不同的组别,每组平均为40例;其中,对照组患者给予氯氮平治疗,观察组患者给予齐拉西酮联合氯氮平治疗,对比两组患者的阳性与阴性症状量表(PANSS)总分、阳性症状、阴性症状及一般病理症状评分、治疗总有效率。结果治疗前,两组患者的临床症状评分对比无差异(P>0.05);治疗后,观察组的PANSS总分、阳性症状、阴性症状及一般病理症状评分和对照组比较均显著更低(P<0.05)。观察组的治疗总有效率[87.50%(35/40)]明显高于对照组[60.00%(24/40)](P<0.05)。结论齐拉西酮联合氯氮平联合用药治疗难治性精神分裂症疾病患者的效果显著,能够有效控制相关的临床症状,用药的安全性较高。
Objective To explore the clinical efficacy of ziprasidone combined with clozapine in the treatment of refractory schizophrenia.Methods Eighty patients with refractory schizophrenia treated in our hospital from January 2018 to June 2019 were divided into two groups by random number table,with an average of 40 cases in each group.The patients in the control group were treated with clozapine,while the patients in the observation group were treated with ziprasidone combined with clozapine.The total score of positive and negative symptom scale(PANSS),the score of positive symptom,negative symptom and general pathological symptom,and the total effective rate of treatment were compared between the two groups.Results Before treatment,there was no significant difference in clinical symptom scores between the two groups(P>0.05);after treatment,the total score of PANSS,positive symptoms,negative symptoms and general pathological symptoms in the observation group were significantly lower than those in the control group(P<0.05).The total effective rate of the observation group was[87.50%(35/40)],which was significantly higher than that of the control group[60.00%(24/40)](P<0.05).Conclusion Ziprasidone combined with clozapine has significant therapeutic efficacy in the treatment of patients with refractory schizophrenia,which can effectively control the relevant clinical symptoms and has high safety.
作者
李莉
LI Li(Shenyang Mental Health Center,Shenyang 110168,China)
出处
《中国医药指南》
2022年第8期74-76,共3页
Guide of China Medicine
